Publications by the researcher in collaboration with Ángel Ramírez Payer (15)

2023

  1. BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia

    Cancer Immunology, Immunotherapy, Vol. 72, Núm. 7, pp. 2529-2539

2021

  1. Btla/hvem axis induces nk cell immunosuppression and poor outcome in chronic lymphocytic leukemia

    Cancers, Vol. 13, Núm. 8

  2. Lag‐3 blockade with relatlimab (Bms‐986016) restores anti‐leukemic responses in chronic lymphocytic leukemia

    Cancers, Vol. 13, Núm. 9

2020

  1. Mechanisms of apoptosis resistance to NK cell-mediated cytotoxicity in cancer

    International Journal of Molecular Sciences, Vol. 21, Núm. 10

2019

  1. Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia

    Haematologica, Vol. 104, Núm. 3, pp. 576-586

  2. The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling

    Frontiers in Immunology, Vol. 10

2018

  1. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia

    Leukemia, Vol. 32, Núm. 3, pp. 645-653

  2. Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia

    Frontiers in immunology, Vol. 9, pp. 2917

  3. The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia

    Leukemia and Lymphoma, Vol. 59, Núm. 10, pp. 2318-2326

2017

  1. Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia

    OncoImmunology, Vol. 6, Núm. 10

2015

  1. Non-coding recurrent mutations in chronic lymphocytic leukaemia

    Nature, Vol. 526, Núm. 7574, pp. 519-524

2014

  1. Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia.Correlation with progressive disease

    PLoS ONE, Vol. 9, Núm. 10

  2. Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells

    BioMed Research International, Vol. 2014

  3. Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome

    Blood, Vol. 123, Núm. 24, pp. 3790-3796

2013

  1. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome

    Leukemia, Vol. 27, Núm. 5, pp. 1100-1106